Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 7/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21214015 | 0.98 | GNAO1 (0.38) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL21677540 | 0.98 | GNAO1 (0.38) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL27279285 | 0.98 | GNAO1 (0.38) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL18799744 | 0.98 | GNAO1 (0.38) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL22068564 | 0.98 | GNAO1 (0.38) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL21166136 | 0.96 | GNAO1 (0.37) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL20243856 | 0.96 | GNAO1 (0.37) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL21008273 | 0.94 | GNAI3 (0.32) | GNAO1GNAI3GNAI1NPC1KDM4E | |
| SCHEMBL18745833 | 0.92 | GNAI3 (0.33) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL21677324 | 0.90 | GNAO1 (0.36) | GNAO1GNAI3GNAI1NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767337-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | GNAO1 2593/4885GNAI3 2326/4885GNAI1 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.